Pharma in Focus - knowledge is power

6 - 12 Sep 2010

Drug Tracker: CE rejection rate problematic for pricing
The latest Drug Tracker analysis of PBAC outcomes shows that an increasing rejection rate for major cost-effectiveness submissions may have potential to affect return on investment for new drugs and indications

Roche reacts to changing pharma environment
Roche has wasted no time in reacting to a series of delays and disappointments that have affected its business over recent months and to changing pressures in the world of drug funding

Subscribe to Pharma in Focus

Sign Up Now

What you'll pay

A two week trial of Pharma in Focus is FREE of charge.

Paid subscription to Pharma in Focus costs $359.95 per year.

Special rates for groups of five or more are also available.
For further information, contact our sales department on 02 9972 0125

3 Simple Steps

	Fill in your details below and submit
	Make your subscription choice
	Make your payment choice (Credit Card, Direct Deposit or Cheque)

Email Address
Retype your Email Address
First Name
Last name
Company or Organisation
Position
Phone
Prove you are human

Send me News Alerts as	HTML (colourful) OR Text only

Note: When your subscription has expired we hope you will renew it but we will continue to send you the daily Pharma in Focus News Alert whether you renew or not. You can unsubscribe from this service at any time. Access: Full text access is immediate upon email verification. Privacy policy: The list on which your email address appears is protected and will not be sold or passed on to any other organisation or individual.

TOP | BACK

Instant Update - Tues 6 Sept
..full report

Roche reviews global job numbers
..full report

Sigma slapped with class action
..full report

Common code considered likely
..full report

Abbott's Reductil patent upheld
..full report

PBS processes given IT overhaul
..full report

Arimidex competitors line up
..full report

Codeine combos still a problem
..full report